The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

There is a simple discount patient access scheme for efanesoctocog alfa. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

There is a simple discount patient access scheme for anhydrous sodium thiosulfate. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can ...

NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...

Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments. There is ...

Access to hybrid closed loop systems will be through a 5‑year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing, contact Leigh.Carr@supplychain ...

NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because ...